MLYSHealthcareMid-Cap
Mineralys Therapeutics, Inc. Insider Trading Activity
Every SEC Form 4 insider transaction reported for Mineralys Therapeutics, Inc. (MLYS), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud Research Team · SEC Form 4 & insider trading data analysts
Last updated:
Quick Answer
Are MLYS insiders buying or selling?
Mineralys Therapeutics, Inc. insiders reported 17 open-market buys ($142.7M) and 64 sells ($102.1M) across 81 Form 4 filings — a net buying position of $40.5M.
Source: SEC EDGAR Form 4
Key Statistics (as of Jul 21, 2026)
Total Form 4 filings
81
SEC EDGAR
Insider filers
11
Insider buys (17)
$142.7M
Insider sells (64)
$102.1M
Insider sentiment
Net buyingNet insider flow of $40.5M in net buying.
Recent MLYS insider transactions
| Date | Insider | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jul 21, 2026 | David Malcom Rodman | Chief Medical Officer | Sale | 416 | $26.53 | $11.0K |
| Jul 16, 2026 | Jon Congleton | Chief Executive Officer | Sale | 10.7K | $27.24 | $291.4K |
| Jul 16, 2026 | David Malcom Rodman | Chief Medical Officer | Sale | 20.4K | $27.28 | $556.7K |
| Jul 10, 2026 | David Malcom Rodman | Chief Medical Officer | Sale | 2.2K | $30.30 | $65.8K |
| Jun 30, 2026 | Jon Congleton | Chief Executive Officer | Sale | 75.0K | $26.14 | $2.0M |
| Jun 30, 2026 | Eric Warren | Chief Commercial Officer | Sale | 104.1K | $25.90 | $2.7M |
| Jun 18, 2026 | David Malcom Rodman | Chief Medical Officer | Sale | 14.5K | $24.19 | $350.1K |
| Jun 18, 2026 | Daphne Karydas | Director | Sale | 3.0K | $25.00 | $75.0K |
| Jun 12, 2026 | David Malcom Rodman | Chief Medical Officer | Sale | 8.5K | $24.20 | $206.2K |
| May 19, 2026 | David Malcom Rodman | Chief Medical Officer | Sale | 417 | $27.55 | $11.5K |
| May 14, 2026 | David Malcom Rodman | Chief Medical Officer | Sale | 22.6K | $28.91 | $652.6K |
| Apr 21, 2026 | David Malcom Rodman | Chief Medical Officer | Sale | 416 | $31.33 | $13.0K |
| Apr 16, 2026 | David Malcom Rodman | Chief Medical Officer | Sale | 20.4K | $26.89 | $548.7K |
| Apr 16, 2026 | Jon Congleton | Chief Executive Officer | Sale | 15.7K | $26.83 | $422.0K |
| Apr 14, 2026 | David Malcom Rodman | Chief Medical Officer | Sale | 2.2K | $27.38 | $59.4K |
| Apr 2, 2026 | Jon Congleton | Chief Executive Officer | Sale | 75.0K | $26.27 | $2.0M |
| Apr 2, 2026 | Daphne Karydas | Director | Sale | 3.0K | $25.00 | $75.0K |
| Mar 31, 2026 | Peter Kolchinsky | Director | Purchase | 369.0K | $23.75 | $8.8M |
| Mar 17, 2026 | David Malcom Rodman | Chief Medical Officer | Sale | 417 | $25.65 | $10.7K |
| Mar 16, 2026 | David Malcom Rodman | Chief Medical Officer | Sale | 20.4K | $26.61 | $543.0K |
| Mar 10, 2026 | David Malcom Rodman | Chief Medical Officer | Sale | 2.2K | $26.84 | $58.3K |
| Feb 17, 2026 | David Malcom Rodman | Chief Medical Officer | Sale | 417 | $27.59 | $11.5K |
| Feb 14, 2026 | David Malcom Rodman | Chief Medical Officer | Sale | 20.4K | $27.93 | $569.8K |
| Feb 11, 2026 | David Malcom Rodman | Chief Medical Officer | Sale | 2.2K | $30.21 | $65.6K |
| Jan 21, 2026 | David Malcom Rodman | Chief Medical Officer | Sale | 416 | $32.10 | $13.4K |
Showing the 25 most recent of 81 Form 4 filings for Mineralys Therapeutics, Inc..
Most active MLYS insiders
- David Malcom Rodman33 filings
- Jon Congleton18 filings
- Adam Scott Levy11 filings
- Brian Taylor Slingsby4 filings
- Peter Kolchinsky4 filings
Ask anything about MLYS insider activity
Use Trabud's AI agent to query Mineralys Therapeutics, Inc.'s Form 4 history in plain English — "Show me MLYS CEO purchases this year" or compare it against any other ticker.
Open the AI agentMLYS insider trading FAQ
Are Mineralys Therapeutics, Inc. insiders buying or selling?
Across 81 SEC Form 4 filings, Mineralys Therapeutics, Inc. (MLYS) insiders reported 17 open-market purchases totaling $142.7M and 64 sales totaling $102.1M. That is a net buying position of $40.5M.
How many insiders trade MLYS stock?
11 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for Mineralys Therapeutics, Inc.. The most recent filing was accepted on Jul 21, 2026.
Where does Trabud get MLYS insider trading data?
All MLYS insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.
Looking for another company? Browse all tracked companies.